Muscimol hydrobromide CAS: 18174-72-6

CAS NO: 18174-72-6
Muscimol hydrobromide
Chemical Name: MUSCIMOL HYDRATE
Molecular Formula: C4H6N2O2.BrH
Formula Weight: 195.01
CAS No.: 18174-72-6
Description Review
Description

Muscimol hydrobromide CAS: 18174-72-6 is a psychoactive compound that is naturally found in certain mushrooms. It has been studied for its potential therapeutic applications in the treatment of anxiety, depression, and other neurological disorders.




Introduce this product:

Muscimol hydrobromide CAS: 18174-72-6 is a psychoactive compound that is naturally found in certain mushrooms. It functions as a potent GABA receptor agonist and has been extensively studied for its potential therapeutic applications in the treatment of anxiety, depression, and other neurological disorders.

Chemical name:

The chemical name of Muscimol hydrobromide CAS: 18174-72-6 is (RS)-5-Amino-1-(2,3-dihydroxypropyl)-1H-imidazole hydrobromide.

Molecular formula:

The molecular formula of Muscimol hydrobromide CAS: 18174-72-6 is C4H7BrN2O2.

Formula weight:

The formula weight of Muscimol hydrobromide CAS: 18174-72-6 is 199.02 g/mol.

CAS No:

The CAS number of Muscimol hydrobromide CAS: 18174-72-6 is 18174-72-6.

Top ten keywords from Google and Synonyms:

  1. Psychoactive Compound
  2. GABA Receptor Agonist
  3. Neurological Disorders
  4. Anxiety
  5. Depression
  6. Natural Mushrooms
  7. Hallucinogen
  8. Sedative
  9. Insomnia
  10. Medical Research

Synonyms:

  • Imbamol
  • 3-Hydroxy-5-aminomethylisoxazole hydrobromide
  • Agarin Hydrobromide

Health benefits of this product:

Muscimol hydrobromide CAS: 18174-72-6 has been studied for its potential therapeutic applications in the treatment of anxiety, depression, and other neurological disorders. It functions as a potent GABA receptor agonist, which can help promote relaxation, reduce anxiety, and improve sleep.

Potential effects:

Muscimol hydrobromide CAS: 18174-72-6 functions as a potent GABA receptor agonist, which can help promote relaxation, reduce anxiety, and improve sleep. It has also been shown to have sedative and hallucinogenic effects at higher doses.

Product mechanism:

Muscimol hydrobromide CAS: 18174-72-6 functions as a potent GABA receptor agonist. GABA is a neurotransmitter in the central nervous system that plays a critical role in regulating neuronal excitability. By binding to GABA receptors, Muscimol can enhance the inhibitory effects of GABA, resulting in a reduction in neuronal activity and promoting relaxation, reducing anxiety and improving sleep.

Safety:

Muscimol hydrobromide CAS: 18174-72-6 can be potentially dangerous when used improperly or abused. Overdose can lead to severe toxicity, including hallucinations, seizures, and respiratory depression. It is important to use it as directed and under the supervision of a healthcare provider to minimize the risk of toxicity.

Side effects:

Some possible side effects of Muscimol hydrobromide CAS: 18174-72-6 include drowsiness, confusion, and impaired coordination. These side effects are more likely to occur at higher doses or with long-term use.

Dosing information:

The dosing information for Muscimol hydrobromide CAS: 18174-72-6 will depend on the specific medical condition being treated and should be determined by a healthcare provider. As it can be potentially dangerous when used improperly or abused, it is essential to use it as directed and under the supervision of a healthcare provider to minimize the risk of toxicity.

Conclusion:

Muscimol hydrobromide CAS: 18174-72-6 is a potent psychoactive compound that is naturally found in certain mushrooms. It functions as a potent GABA receptor agonist and has been extensively studied for its potential therapeutic applications in the treatment of anxiety, depression, and other neurological disorders. While further research is needed to fully understand the potential health benefits and applications of Muscimol hydrobromide, it has shown promise in clinical studies. However, it can be potentially dangerous when used improperly or abused, and it is important to use it as directed and under the supervision of a healthcare provider to minimize the risk of toxicity

Tiagabine Atropine Bicuculline Hallucinogen Benzodiazepine Prodrug Amanita muscaria Flumazenil

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code